Literature DB >> 27658536

Phase I/II study of low-dose azacytidine in patients with chronic myeloid leukemia who have minimal residual disease while receiving therapy with tyrosine kinase inhibitors.

Abhishek Maiti1,2, Jorge E Cortes2, Yolanda D Brown2, Hagop M Kantarjian2.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2016        PMID： 27658536      PMCID： PMC5250544          DOI： 10.1080/10428194.2016.1207767

Source DB:  PubMed          Journal:  Leuk Lymphoma        ISSN： 1026-8022


× No keyword cloud information.
  14 in total

1.  Quantitative measure of c-abl and p15 methylation in chronic myelogenous leukemia: biological implications.

Authors:  T T Nguyen; A F Mohrbacher; Y C Tsai; J Groffen; N Heisterkamp; P W Nichols; M C Yu; M Lübbert; P A Jones
Journal:  Blood       Date:  2000-05-01       Impact factor: 22.113

2.  Discontinuation of imatinib in patients with chronic myeloid leukaemia who have maintained complete molecular remission for at least 2 years: the prospective, multicentre Stop Imatinib (STIM) trial.

Authors:  François-Xavier Mahon; Delphine Réa; Joëlle Guilhot; François Guilhot; Françoise Huguet; Franck Nicolini; Laurence Legros; Aude Charbonnier; Agnès Guerci; Bruno Varet; Gabriel Etienne; Josy Reiffers; Philippe Rousselot
Journal:  Lancet Oncol       Date:  2010-10-19       Impact factor: 41.316

3.  Phase II study of low-dose decitabine in patients with chronic myelogenous leukemia resistant to imatinib mesylate.

Authors:  Jean-Pierre J Issa; Vazganush Gharibyan; Jorge Cortes; Jaroslav Jelinek; Gail Morris; Srdan Verstovsek; Moshe Talpaz; Guillermo Garcia-Manero; Hagop M Kantarjian
Journal:  J Clin Oncol       Date:  2005-05-09       Impact factor: 44.544

4.  Expression of DNA methyltransferases DNMT1, 3A, and 3B in normal hematopoiesis and in acute and chronic myelogenous leukemia.

Authors:  S Mizuno ; T Chijiwa; T Okamura; K Akashi; Y Fukumaki; Y Niho; H Sasaki
Journal:  Blood       Date:  2001-03-01       Impact factor: 22.113

5.  Methylation of the ABL1 promoter in chronic myelogenous leukemia: lack of prognostic significance.

Authors:  J P Issa; H Kantarjian; A Mohan; S O'Brien; J Cortes; S Pierce; M Talpaz
Journal:  Blood       Date:  1999-03-15       Impact factor: 22.113

6.  In vitro efficacy of combined treatment depends on the underlying mechanism of resistance in imatinib-resistant Bcr-Abl-positive cell lines.

Authors:  Paul La Rosée; Kara Johnson; Amie S Corbin; Eric P Stoffregen; Erika M Moseson; Stephanie Willis; Michael M Mauro; Junia V Melo; Michael W Deininger; Brian J Druker
Journal:  Blood       Date:  2003-08-21       Impact factor: 22.113

Review 7.  Insights from pre-clinical studies for new combination treatment regimens with the Bcr-Abl kinase inhibitor imatinib mesylate (Gleevec/Glivec) in chronic myelogenous leukemia: a translational perspective.

Authors:  P La Rosée; M E O'Dwyer; B J Druker
Journal:  Leukemia       Date:  2002-07       Impact factor: 11.528

8.  Cadherin-13, a mediator of calcium-dependent cell-cell adhesion, is silenced by methylation in chronic myeloid leukemia and correlates with pretreatment risk profile and cytogenetic response to interferon alfa.

Authors:  Jose Roman-Gomez; Juan A Castillejo; Antonio Jimenez; Francisco Cervantes; Concepcion Boque; Lourdes Hermosin; Angel Leon; Albert Grañena; Dolors Colomer; Anabel Heiniger; Antonio Torres
Journal:  J Clin Oncol       Date:  2003-04-15       Impact factor: 44.544

9.  Relative survival in patients with chronic-phase chronic myeloid leukaemia in the tyrosine-kinase inhibitor era: analysis of patient data from six prospective clinical trials.

Authors:  Koji Sasaki; Sara S Strom; Susan O'Brien; Elias Jabbour; Farhad Ravandi; Marina Konopleva; Gautam Borthakur; Naveen Pemmaraju; Naval Daver; Preetesh Jain; Sherry Pierce; Hagop Kantarjian; Jorge E Cortes
Journal:  Lancet Haematol       Date:  2015-04-20       Impact factor: 18.959

Review 10.  European LeukemiaNet recommendations for the management of chronic myeloid leukemia: 2013.

Authors:  Michele Baccarani; Michael W Deininger; Gianantonio Rosti; Andreas Hochhaus; Simona Soverini; Jane F Apperley; Francisco Cervantes; Richard E Clark; Jorge E Cortes; François Guilhot; Henrik Hjorth-Hansen; Timothy P Hughes; Hagop M Kantarjian; Dong-Wook Kim; Richard A Larson; Jeffrey H Lipton; François-Xavier Mahon; Giovanni Martinelli; Jiri Mayer; Martin C Müller; Dietger Niederwieser; Fabrizio Pane; Jerald P Radich; Philippe Rousselot; Giuseppe Saglio; Susanne Saußele; Charles Schiffer; Richard Silver; Bengt Simonsson; Juan-Luis Steegmann; John M Goldman; Rüdiger Hehlmann
Journal:  Blood       Date:  2013-06-26       Impact factor: 22.113
View more
  1 in total

Review 1.  Third-line therapy for chronic myeloid leukemia: current status and future directions.

Authors:  Jorge Cortes; Fabian Lang
Journal:  J Hematol Oncol       Date:  2021-03-18       Impact factor: 17.388
  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.